🔎 Trials Near Me

መነሻ › Multiple Myeloma › Oregon › Portland

በPortland፣ OR ለMultiple Myeloma የሚደረጉ ክሊኒካዊ ጥናቶች

ለMultiple Myeloma የሚደረጉ 13 ጥናቶች በPortland እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Research Site, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT07391657

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Oregon Health And Science University, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07258511

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • OHSU Knight Cancer Institute, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06784167

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Providence Health & Services, Portland
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Oregon Health and Science University, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Oregon Health and Science University /ID# 272282, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06953960

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Providence Portland Medical Center, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07075185

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Research Site, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኦገስ 2026 · NCT07764978

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Oregon Health & Science University, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT05469893

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 ማይል ርቀት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ10 ጁን 2026 · NCT05561387

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኤፕሪ 2026 · NCT03761108

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Local Institution - 0016, Portland
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጃንዩ 2026 · NCT06357754

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • Oregon Health Sciences University, Portland
እድሜ 40 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ጃንዩ 2026 · NCT05366881

በሌሎች ከተሞች ለMultiple Myeloma የሚደረጉ ጥናቶች

በPortland ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።